6 recruiting, 2 active not recruiting, 2 terminated. 10 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 6, Active not recruiting 2, Terminated 2 |
| Phase 1 | 4 | Recruiting 3, Active not recruiting 1 |
Follow MCL: new trials by email Literature Review of MCL trials Research Report on MCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study Acalabrutinib, Rituximab, Glofitamab - Phase 2 Study, MCL | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-04-01 | 2026-05-20 |
| Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma BAFF-R CAR-T - DLBCL, CLL | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-11-29 | 2026-05-13 |
| Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma Glofitamab, Lenalidomide - MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Peking University Third Hospital | 43 | 2025-08-11 | 2026-03-10 |
| A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. Sonrotoclax, Zanubrutinib - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 258 | 2025-01-23 | 2026-10-26 |
| Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients BGB-11417, BGB-3111, CD20 - MCL | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-08-01 | 2025-05-11 |
| Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). CD19/CD22-CAR T cells - Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-07-10 | 2025-08-06 |
| A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma Tafasitamab, Lenalidomide - Mantle Cell Lymphoma, MCL | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 4 | 2023-03-14 | 2025-05-25 |
| Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma - MCL, Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Nordic Lymphoma Group | 81 | 2021-12-15 | 2024-02-12 |
| First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma Epcoritamab - DLBCL, High-grade B-cell Lymphoma (HGBCL) | Phase 1 / Phase 2 | Active not recruiting | Genmab | 666 | 2018-06-26 | 2026-11-04 |
| Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas 90Y-DOTATOC - DLBCL, MCL | Phase 2 | Terminated | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 1 | 2016-12-22 | 2018-03-19 |
Lymphoma, Mantle-Cell (5) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Recurrence (2) · Hematologic Neoplasms (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma, Non-Hodgkin (6) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Hematologic Diseases (3) · Leukemia (3) · Leukemia, Lymphoid (3)
zanubrutinib (3) · Lenalidomide (2) · glofitamab (2) · 90Y-octreotide, DOTA-Tyr(3)- (1) · Rituximab (1) · acalabrutinib (1) · tafasitamab (1)
BeOne Medicines (1) · Essen Biotech (1) · Genmab (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Nordic Lymphoma Group (1) · Peking University Third Hospital (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (5) · United States (4) · Australia (2) · Denmark (2) · Finland (2) · France (2) · Italy (2) · South Korea (2) · Sweden (2) · United Kingdom (2) · Brazil (1) · Canada (1) · Germany (1) · Netherlands (1) · Norway (1)
Anita Kumar, MD (1) · Maddalena Sansovini, MD (1) · Mats Jerkeman (1) · Preetesh Jain, MD (1)
PMID 34508654, PMID 36548927, PMID 38151388, PMID 38889737, PMID 39322711, PMID 40472301, PMID 42411504, PMID 42431612, PMID 42541678
2017 (1), 2023 (1)